Predictive Oncology Inc. (NASDAQ: POAI) received a notification letter from Nasdaq confirming compliance with minimum stockholders’ equity requirements, allowing shares to continue trading under the ticker “POAI.” The company’s CFO, Josh Blacher, emphasized the strengthening of the financial position and commitment to a digital asset treasury strategy focused on the Aethir ecosystem. Predictive Oncology utilizes AI and machine learning for early drug discovery, boasting a 92% accuracy rate in predicting tumor response to specific drug compounds. The company also operates a digital asset treasury focused on the Aethir (ATH) token to create a Strategic Compute Reserve, aiming to democratize access to AI infrastructure.

Read more at GlobeNewswire: Predictive Oncology Regains Compliance with Nasdaq’s